ClinicalTrials.gg
CompletedNCT06792851Updated Jan 27, 2025

ECHO-012 Kosmos Bladder Clinical Validation Study

An interventional study of Kosmos Bladder Volume Algorithm in Bladder Disease, Bladder Retention Volume and Bladder Dysfunction, sponsored by EchoNous Inc.. Completed at 1 site in United States. Open to participants aged 7 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by EchoNous Inc. · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Aug 2024, registered Jan 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Not applicable
Ages
7 Years to 89 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the Kosmos Automatic Bladder Volume to the manual annotated bladder volume in participants across gender (male and female), age (children ages 7-17 and adults 18-89), and BMI strata (low to normal and high BMI). The hypothesis it aims to evaluate is: The Pearson correlation coefficient between Kosmos estimated bladder volume and manually annotated bladder volume will yield more than 0.90.

Participants will:

  • Have their full bladders scanned and bladder volume calculated using the Kosmos Ultrasound Diagnositic System by both a nurse and sonographer.
  • Participants will void and measure their urine volume.
  • Participants empty bladders will be scanned and bladder volume calculated using the Kosmos Ultrasound Diagnositic System again by both a nurse and sonographer.
  • Three sonographers will manually annotate the pre- and post-void exam images for each patient to calculate the manually annotated bladder volume.
02

Conditions studied

  • Bladder Disease
  • Bladder Retention Volume
  • Bladder Dysfunction
  • Bladder Function
03

In context

Urinary Bladder Diseases

62 studies on the registry are indexed under Urinary Bladder Diseases; 9 are open to participants now.

This study's enrollment of 146 is above the median of 79 across 42 interventional studies indexed under Urinary Bladder Diseases.

Browse Urinary Bladder Diseases studies →

Lead sponsor

EchoNous Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Read and sign an English consent form, or assent form, in the case of a minor child
  • Read and complete an English demographic and general health survey, or have an LAR complete it for them in the case of a minor child
  • Give consent for participation, or assent in the case of a minor child
  • Able and willing to comply with study requirements
  • Follow fluid consumption requirements prior to the study visit
  • Those aged 7 years through 89 years, healthy as well as individuals with pelvic region abnormalities (if applicable), including but not limited to:

    i) Bladder cancer ii) Thickened bladder wall iii) Bladder stones iv) Current bladder or urinary tract infection

Exclusion criteria

Exclusion Criteria:

  • Adults over 89 years old
  • Children under the age of 7
  • Persons who are pregnant
  • Persons who report an empty bladder upon arrival at their scheduled study visit
  • Children in foster care, as a foster parent may not legally consent for a foster child
  • Those who cannot or refuse to sign their consent or assent (including those with an LAR willing to provide consent)
  • Those who cannot provide or whose LAR cannot provide consent
  • Those who cannot speak or read English
  • Participants from ECHO-010 Bladder AI Training and Validation Data Collection Study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Bladder Volume Measurement

    Pre- and post-void bladder volume assessment using Kosmos device by both nurse and sonographer and void volume measurement.

    Device: Kosmos Bladder Volume Algorithm

Interventions

  • DeviceKosmos Bladder Volume Algorithm

    Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.

06

What researchers measure

Primary outcomes

  1. Manual Bladder Volume vs. Kosmos Automated Bladder Volume

    Kosmos Automated Bladder Volume and exam images will be captured using the Kosmos Ultrasound Diagnostic System by a nurse and a sonographer for each participant with both a full and empty bladder. Three independent sonographers will manually measure exam images for bladder length (L), width (W), and height (H). Volume will be calculated using: Bladder Volume = k×L×D×W where k is the correction coefficient. These results from the three sonographers will be averaged. The Pearson correlation coefficient between the average manual bladder volume and the Kosmos calculated pre-void volume will be calculated using the following equation: r=\[∑(x-xbar)(y-ybar)\]/\[∑(x-xbar)\^2 ∑(y-ybar)\^2\] Where x is the manual bladder volume, y is the Kosmos bladder volume, xbar is the mean of the manual bladder volume, and ybar is the mean of the Kosmos bladder volume. A successful outcome would be a correlation coefficient (r) of \>0.90 on bladder exams acquired by both nurses and sonographers.

    Time frame: Post data acquisition (one month)

07

Study locations

1 site
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Aug 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Aug 5, 2024
Primary completionActual
Aug 15, 2024
CompletionActual
Aug 15, 2024
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06792851
Lead sponsor
EchoNous Inc.
Collaborators
Rainier Clinical Research Center
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Aug 5, 2024
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024
Last update
Jan 27, 2025

Study contacts

Sheryl Marks, M.D.
principal investigator · Rainier Clinical Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion